Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. Forward Looking Information. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Ehave, Inc.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

NORML

APRIL 30, 2020

” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display.”

Chronic Pain 342

Chronic Pain Clinical Trials Data Patients 342

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

NORML

MARCH 30, 2020

By contrast, they reported that there exists “no evidence from properly designed clinical trials to support the use of CBD for the treatment” of these or other conditions, such as the flu, West Nile virus, Ebola, or common cold viruses. However, this data was based solely on preclinical findings.

CBD 296

CBD Clinical Trials Data Treatment 296

NORML

JANUARY 17, 2019

A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. .

Clinical Trials 230

Clinical Trials Legislation DEA Strains 230

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Medical Marijuana Program Connection

FEBRUARY 27, 2023

The cannabis oil will be used as a part of the Company‘s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL. Read More

Clinical Trials 52

Clinical Trials Oil CBD Treatment 52

Veriheal

JANUARY 11, 2023

Not only this, but Gaize recently completed the largest clinical trial into cannabis impairment , and the results are set to transform the realm of workplace and road safety. How do you feel about this being the largest cannabis impairment clinical trial ever? Does Gaize plan on carrying out any future clinical trials?

Clinical Trials 98

Clinical Trials THC Data Safety 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. This will offer professionals worldwide a chance to gain insight into this research, equipping them with valuable information they can apply in their own contexts.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. For further information please visit out website: www.globalwellnessstrategies.com. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. ” Simply put, there is the expectation that ongoing and future clinical trials will further establish therapeutic potential in using psilocybin for OCD.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

NORML

JANUARY 31, 2019

Proposed federal legislation to direct the agency to conduct clinical trials on the use of cannabis for PTSD and for other conditions is currently pending in the US House and Senate. Additional information is available from the NORML fact-sheet, “Marijuana and Veterans Issues,” here.

Clinical Trials 195

Clinical Trials Chronic Pain Data Treatment 195

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

CannaMD

JUNE 2, 2021

Another noteworthy finding of the study was the revelation that more than half of patients using marijuana to treat symptoms of Parkinson’s had not been provided with any information or recommendations on dosage, cannabis type, or frequency of use.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Cannabis Law Report

AUGUST 3, 2021

There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

MARCH 30, 2022

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. Additional information is available from NORML here.

Legislation 95

Legislation Clinical Trials DEA Access 95

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. But if that doctor has access to information from 40,000 patients it’s a different story.

Data 105

Data Clinical Trials Research and Development Indica 105

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. For more information visit www.marinuspharma.com. Conference Call and Webcast Details. Forward-Looking Statements. 484-253-6792.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 9, 2021

Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. Investor: Robert Schatz. 646) 421-9523.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Availability of other information about COMPASS Pathways. The information that we post on these channels and websites could be deemed to be material information. Business highlights. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 23, 2021

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Excellent communication skills, especially in communicating regulations, contingencies, and technical information.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. MediPharm Labs Corp. Logo (CNW Group/MediPharm Labs Corp.). Management Commentary.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

JULY 28, 2021

More information about the organization is available at [link]. Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. MAPS PBC is committed to the evolution of psychedelic healing modalities.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

AUGUST 5, 2021

Thanks to the license, Filament will look to create the first-ever natural pharmaceutical grade extracts and put them into clinical trials in order to demonstrate safety and efficacy. For more information, visit filament.health. Investment summary. FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105